Hisamitsu's HP-3070 meets in Phase III for schizophrenia

Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530) reported data from a double-blind, U.S. Phase III trial in 617 patients with schizophrenia showing that HP-3070 met the primary endpoint of reducing Positive and Negative Syndrome Scale (PANSS) total score from baseline to week six vs. placebo. Additional data are slated for publication at future scientific meetings...